Last reviewed 2026-04-22 · How we verify

Glucagon 12.5ng/kg/min

Glucagon binds to glucagon receptors on hepatic and other cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.

Glucagon binds to glucagon receptors on hepatic and other cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels. Used for Acute hypoglycemia (severe or refractory), Hypoglycemia in critical care settings.

At a glance

Mechanism of action

Glucagon is a peptide hormone that activates G-protein coupled glucagon receptors, primarily on hepatocytes, triggering intracellular signaling cascades that mobilize stored glycogen and promote glucose synthesis. This results in rapid elevation of blood glucose, making it effective for acute hypoglycemia reversal. The dose specified (12.5 ng/kg/min) suggests continuous intravenous infusion, likely for severe or refractory hypoglycemia management in a clinical setting.

Approved indications

• Acute hypoglycemia (severe or refractory)
• Hypoglycemia in critical care settings

Common side effects

• Hyperglycemia
• Nausea
• Vomiting
• Tachycardia
• Hypokalemia

Key clinical trials

• Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Glucagon 12.5ng/kg/min CI brief — competitive landscape report
• Glucagon 12.5ng/kg/min updates RSS · CI watch RSS
• Cambridge University Hospitals NHS Foundation Trust portfolio CI